Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis

BACKGROUND: Advances in Disease-Modifying Antirheumatic Drugs (DMARDs) have expanded the treatment landscape for Rheumatoid Arthritis (RA). Guidelines recommend adding either conventional synthetic (cs), biologic (b), or targeted synthetic (ts) DMARDs to methotrexate (MTX) for managing RA. Limited e...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yinan, Chatterjee, Satabdi, Agarwal, Sandeep K., Chen, Hua, Johnson, Michael L., Aparasu, Rajender R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372178/
https://www.ncbi.nlm.nih.gov/pubmed/37521021
http://dx.doi.org/10.1016/j.rcsop.2023.100296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372178/
https://www.ncbi.nlm.nih.gov/pubmed/37521021
http://dx.doi.org/10.1016/j.rcsop.2023.100296

Ejemplares similares